3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Breast
2
Tumor-Agnostic
1
Myeloid
1
Gastrointestinal
1
Classical hematology
1
CNS
1
Conditions
Thrombocytopenia
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
24
fludarabine phosphate
18
Whole-Body Irradiation
17
fludarabine
16
Mycophenolic Acid
16
Tacrolimus
12
Peripheral Blood Stem Cell Transplantation
12
Busulfan
12
Melphalan
11
apixaban
10
Biopsy
7
Rivaroxaban
6
Granulocyte Colony-Stimulating Factor
6
Specimen Handling
5
Filgrastim
5
Cyclosporine
5
Azacitidine
5
thymoglobulin
4
X-Rays
4
Sirolimus
4
Rituximab
4
Injections
4
Enoxaparin
4
Decitabine
4
Bone Marrow Transplantation
4
Aspirin
4
Antilymphocyte Serum
4
venetoclax
3
pegylated granulocyte colony-stimulating factor
3
hetrombopag
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Tranexamic Acid
×
Classical hematology
×
1 year
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled